Lilly's Quiet Bet on a Gut Hormone You've Never Heard Of

GLP-2 is the lesser-known cousin. Same family of gut hormones, completely different job. While GLP-1 controls appetite and blood sugar, GLP-2 tells your intestinal lining to grow. It triggers stem cells in the gut wall to multiply, builds taller nutrient-absorbing structures called villi, reduces cell death, and increases blood flow to the intestines. Think of GLP-1 as the hormone that says "stop eating" and GLP-2 as the one that says "absorb more of what you eat."

The only approved GLP-2 drug for SBS today is teduglutide, sold as Gattex. It works; some patients can reduce or even eliminate their dependence on IV nutrition. But it requires a daily injection, reconstitution from a powder, and cold-chain storage. For a chronically ill population already tethered to medical equipment, that daily burden matters.

Why Monthly Dosing Could Be a Big Deal

Sonefpeglutide is built on Hanmi's LAPSCOVERY platform, which attaches therapeutic proteins to an antibody fragment using a special polymer linker. The result is a molecule that sticks around in the body much longer than normal.

How much longer? For comparison, teduglutide's half-life in rats was just 0.6 hours; sonefpeglutide's rat half-life was 42.3 hours, roughly 70 times longer. That extended exposure is what makes monthly dosing plausible.

The preclinical results are striking, too. In SBS rats treated with sonefpeglutide, small intestinal weight roughly doubled compared to vehicle-treated controls, and nutrient absorption improved significantly. Those are animal results, not human data, so the usual caveats apply. But for a rare disease with limited options, the signal is encouraging.

Lilly's Bigger GI Ambitions

This deal isn't really about short bowel syndrome alone. Industry observers have been quick to point out that Lilly secured rights to develop sonefpeglutide across multiple indications, not just SBS. Korean financial press reported that market attention is "focused less on SBS itself and more on the rights to multiple indications" that Lilly locked up.

That makes sense when you zoom out. Lilly has been on a dealmaking spree in 2026, fueled by the billions flowing in from Zepbound and Mounjaro. The company is building what amounts to a gut-hormone empire: tirzepatide (GIP/GLP-1) for obesity and diabetes, orforglipron as an oral GLP-1, retatrutide as a triple-agonist for even deeper weight loss, and now sonefpeglutide to cover GLP-2 biology in the intestine.

GLP-2's ability to promote mucosal healing and reduce intestinal inflammation could theoretically be useful in conditions far more common than SBS, including inflammatory bowel disease and other malabsorption disorders. Lilly hasn't announced specific plans, but the deal structure gives it the option to explore.

The Competitive Landscape Is Getting Crowded

Sonefpeglutide isn't the only next-gen GLP-2 in development. Zealand's glepaglutide has an EMA submission in progress for adult SBS, targeting twice-weekly dosing. Ironwood's apraglutide is in Phase 3 with published efficacy data. Both are further along clinically than sonefpeglutide.

But neither offers monthly dosing. If sonefpeglutide's preclinical advantage in dosing frequency holds up in humans, it would have a clear convenience edge in a market where patients are already overwhelmed by their treatment burden. That "if" is doing a lot of heavy lifting, though. We won't know until the Phase 2 data arrive, and those results could be years away.

The Bottom Line

Lilly paid a relatively small upfront price for a potentially big option. $75 million is a rounding error for a company generating Zepbound-level revenue. The back-loaded milestone structure means most of the financial commitment only kicks in if the drug proves itself in the clinic and at the pharmacy counter.

For Hanmi, this is validation. The South Korean company has built an impressive track record of licensing LAPSCOVERY-based drugs to global pharma, including previous deals with Merck (a GLP-1/glucagon dual agonist for NASH worth up to $870 million) and an FDA-approved neutropenia drug called rolontis. The Lilly deal is its biggest yet.

For SBS patients, the stakes are more personal. About the only approved drug that addresses their underlying disease requires a needle every single day. If sonefpeglutide works as hoped, that could drop to once a month. In a disease defined by constant medical dependency, that kind of freedom would be transformative.

Of course, preclinical promise and clinical proof are separated by a canyon that swallows most drug candidates. Lilly is betting it can cross it. The next few years will tell us whether that bet pays off.

The Cancer That Had No Good Options Just Got One

Merck's antibody-drug conjugate sac-TMT just became the first ADC to beat chemotherapy on both overall survival and progression-free survival in advanced endometrial cancer. For patients who'd exhausted chemo and immunotherapy, this Phase 3 win could rewrite the treatment playbook.